Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Metastatic cancer
Trial Type:  Treatment
Results 1-25 of 166 for your search:
Start Over
Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older
Status: Active
Phase: Phase IV
Type: Treatment
Age: 70 and over
Trial IDs: 1200.209, NCI-2016-00277, NCT02514174
Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients with Localized Spine Metastasis
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: RTOG 0631, NCI-2009-01687, CDR0000646803, NCT00922974
Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: TS-102, NCI-2012-00575, NCT01483027
Stereotactic Radiosurgery or Whole Brain Radiation Therapy in Treating Patients with Newly Diagnosed Non-melanoma Brain Metastases
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 2011-0884, NCI-2014-02058, NCI-2012-00850, NCT01592968
Phase III Study of DCVAC Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: SP005, NCI-2014-02085, 2012-002814-38, NCT02111577
Single-Fraction or Hypofractionated Stereotactic Radiosurgery in Treating Patients with Spinal Metastases
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 14-233, NCI-2014-02624, NCT02320825
A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CR107614, NCI-2016-00191, 2015-000735-32, 56021927PCR3002, NCT02489318
Percutaneous Hepatic Perfusion vs Best Alternative Care in Patients With Hepatic-dominant Ocular Melanoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PHP-OCM-301, NCI-2016-00242, NCT02678572
Embolization Therapy with or without Chemotherapy in Controlling Liver Metastases in Patients with Neuroendocrine Tumor Metastases to the Liver That Cannot Be Removed by Surgery
Status: Active
Phase: Phase III
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: UPCC01215, NCI-2016-00610, NCT02724540
Trastuzumab in Treating Leptomeningeal Metastases in Patients with HER2-Positive Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 10C03, NCI-2011-00110, STU00040150, STU00040150-MOD0003, NCT01325207
Imiquimod, Cyclophosphamide, and Radiation Therapy in Treating Patients with Breast Cancer with Skin Metastases
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: NYU 11-00598, NCI-2011-02879, NCT01421017
Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod Before Surgery in Treating Patients With Recurrent or Metastatic Colorectal Cancer That Can Be Removed By Surgery
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCI 10-131, NCI-2013-00076, NCT01545141
Hydroxychloroquine and Aldesleukin in Treating Patients With Metastatic Kidney Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IIT11PLK01, NCI-2012-00427, 1302010628, 11-080, NCT01550367
Stereotactic Radiosurgery in Treating Patients with Large Brain Metastases
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CASE8312, NCI-2013-00845, NCT01843413
Quinacrine Hydrochloride and Capecitabine in Treating Patients with Metastatic or Recurrent Colorectal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: GI-078, NCI-2016-00139, NCT01844076
Radiosurgery Before Surgery in Treating Patients with Brain Metastases That Can be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CASE 7312, NCI-2013-00644, NCT01891318
Vaccine Therapy and Iscomatrix with or without Cyclophosphamide and Celecoxib in Treating Patients with Thoracic Malignancies or Tumors That Have Spread to the Chest Cavity
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-C-0053, NCI-2014-02465, 140053, P131392, 348360, NCT02054104
Genetically Engineered Lymphocytes and Aldesleukin after Cyclophosphamide and Fludarabine Phosphate in Treating Patients with Metastatic or Locally Advanced Refractory/Recurrent Cancer That Expresses MAGE-A3
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 66
Trial IDs: 14-C-0110, NCI-2014-02496, P131467, 1402-1293, RD-14-III-03, 140110, 338101, NCT02153905
Ipilimumab and Hypofractionated Stereotactic Body Radiation Therapy in Treating Patients with Advanced Solid Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-0882, NCI-2015-00042, NCT02239900
Stereotactic Body Radiation Therapy in Treating Patients with Painful Bone Metastases
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: STAT-RT-1/2, NCI-2014-00968, 16964, STAT RAD 2, NCT02145286
Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 391402, NCI-2015-01741, NCT02540356
A Trial of AP32788 in Non-Small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AP32788-15-101, NCI-2016-00587, NCT02716116
Nivolumab and Radiation Therapy with or without Ipilimumab in Treating Patients with Brain Metastases from Non-Small Cell Lung Cancer
Status: Not yet active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2015-0883, NCI-2016-00661, NCT02696993
Cyclodextrin-based polymer-camptothecin CRLX101 and Olaparib in Treating Patients with Relapsed or Refractory Small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16-C-0107, NCI-2016-00748, P152527, NCT02769962
Start Over